(MedPage Today) — A single infusion of the interleukin (IL)-6 inhibitor tocilizumab (Actemra) showed greater improvements in depression severity, somatic symptoms, fatigue, and anxiety in patients with difficult-to-treat depression and low-grade…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
